Journal article
Preeclampsia does not share common risk alleles in 9p21 with coronary artery disease and type 2 diabetes
T Kaartokallio, AI Lokki, H Peterson, K Kivinen, L Hiltunen, E Salmela, T Lappalainen, P Maanselkä, S Heino, S Knuutila, A Sayed, L Poston, SP Brennecke, MP Johnson, L Morgan, EK Moses, J Kere, H Laivuori
Annals of Medicine | TAYLOR & FRANCIS LTD | Published : 2016
Abstract
Introduction: Preeclampsia is a common and partially genetic pregnancy complication characterized by hypertension and proteinuria. Association with cardiovascular disease and type 2 diabetes has been reported in 9p21 by several genome-wide association studies. It has been hypothesized that cardiometabolic diseases may share common etiology with preeclampsia. Materials and methods: We tested association with the 9p21 region to preeclampsia in the Finnish population by genotyping 23 tagging single nucleotide polymorphisms (SNPs) in 15 extended preeclampsia families and in a nationwide cohort consisting of 281 cases and 349 matched controls. Replication was conducted in additional datasets. Res..
View full abstractGrants
Awarded by Australian National Health and Medical Research Council
Awarded by National Institutes of Health of the USA
Funding Acknowledgements
[ "This study was supported by Academy of Finland; Finnish Medical Foundation, Jane and Aatos Erkko Foundation; Sigrid Juselius Foundation, Paivikki and Sakari Sohlberg Foundation; Research Funds of the University of Helsinki; Government Special state subsidy for Health Sciences (EVO funding) at Helsinki and Uusimaa Hospital District.", "Tea Kaartokallio was supported by Doctoral Programme in Biomedicine (DPBM), Doctoral Programme in Clinical Research (KLTO), Research Foundation of the University of Helsinki and Biomedicum Helsinki Foundation.", "Ayat Sayed was supported by a grant from the Egyptian Ministry of Higher Education.", "Elina Salmela was supported by Antti and Jenny Wihuri Foundation.", "Tuuli Lappalainen was supported by Emil Aaltonen Foundation.", "The Australian and New Zealand component of the study were funded by grants from the Australian National Health and Medical Research Council (# 1053152) and the National Institutes of Health of the USA (# HD049847). Funding for the UK VIP (vitamins in pre-eclampsia) trial was provided by the Wellcome Trust." ]